References
- Hekimsoy Z, Payzin B, Örnek T, Kandoğan G. Mean platelet volume in Type 2 diabetic patients. J Diabetes Compl 2004; 18: 173–176
- Sharpe PC, Trinick T. Mean platelet volume in diabetes mellitus. Quart J Med 1993; 86: 739–742
- Papanas N, Symeonidis G, Maltezos E, Mavridis G, Karavageli E, Vosnakidis T. Mean platelet volume in patients with type 2 diabetes mellitus. Platelets 2004; 15: 475–478, et al.
- Feldman EL, Stevens MJ, Thomas PK, Brown MB, Canal N, Greene DA. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care 1994; 17: 1281–1289
- Sima AAF. New insights into the metabolic and molecular basis for diabetic neuropathy. Cell Mol Life Sci 2003; 60: 2445–2464
- The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20: 183–197
- Papanas N, Papatheodorou K, Christakidis D, Papazoglou D, Giassakis G, Piperidou H. Evaluation of a new indicator test for sudomotor function (Neuropad®) in the diagnosis of peripheral neuropathy in type 2 diabetic patients. Exp Clin Endocrinol Diabetes 2005; 113: 195–198, et al
- O’Malley BC, Ward JD, Timperley WR, Porter NR, Preston FE. Platelet abnormalities in diabetic peripheral neuropathy. Lancet 1975; iv: 1274–1276
- Jennings PE, Dallinger KJ, Nightingale S, Barnett AH. Abnormal platelet aggregation in chronic symptomatic diabetic peripheral neuropathy. Diabet Med 1986; 3: 237–240
- Hara T, Nakamura J, Koh N, Sakakibara F, Hamada Y, Sasaki H. An aldose reductase inhibitor, TAT, reduces ADP-induced platelet hyperaggregation in streptozotocin-induced diabetic rats with neuropathy. J Lab Clin Med 1995; 126: 541–547, et al
- Ueno Y, Koike H, Nakamura Y, Ochi Y, Annoh S, Nishio S. Effects of beraprost sodium, a prostacyclin analogue, on diabetic neuropathy in streptozotocin-induced diabetic rats. Jpn J Pharmacol 1996; 70: 177–182